AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04228562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: induction of anticipated regret
Description: higher level of elaboration on potential regret
Study NCT03332303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrace® Cream
Description: Estrace® Cream
Study NCT03332303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Vaginal Cream
Description: Estradiol Vaginal Cream
Study NCT01102374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Vitamin D
Description: Vitamin D 12,000 IU monthly
Study NCT01102374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo monthly
Study NCT01102374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Study NCT03332303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle Cream
Study NCT02213822 — intervention group
Intervention type: OTHER
Intervention: Molecular Analysis of Cancer
Description: The intervention performed in this study is the molecular analysis of cancer. Samples to be tested for genetic alterations will be collected during the course of a routine diagnostic procedure such as a surgery or tumor biopsy. Samples that have been stored from previous diagnostic procedures will be analyzed as well. This testing will be performed by the Department of Pathology at Rhode Island Hospital or an outside laboratory designated by Rhode Island Hospital. The extent of molecular testing will be different in each individual case. For example, in some cases, study of genetic alterations will start with whole genome or exome sequencing and will be confirmed by targeted Sanger resequencing, single nucleotide polymorphism, and transcriptome analysis. In other cases targeted multigene panel sequencing or targeted amplicon Sanger sequencing will be the initial and only step.
Study NCT01884961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boost of radiotherapy + high dose IL-2 treatment
Description: Boost of radiotherapy + high dose IL-2 treatment
Study NCT02452177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT00526461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: IV
Study NCT01332604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral escalating dose
Study NCT01332604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose
Study NCT01332604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Oral repeating dose
Study NCT01332604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Intravenous repeating dose
Study NCT00807300 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT-guided brachytherapy
Description: catheter placed into the tumor by CT-guidance, radiation with iridium 192
Study NCT00807300 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: transarterial chemoembolization
Description: application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery
Study NCT02205918 — intervention group
Intervention type: OTHER
Intervention: Active TMS
Description: There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive 1hz active TMS. Tics and urges will be monitored immediately before and after TMS.
Study NCT02205918 — intervention group
Intervention type: OTHER
Intervention: Sham TMS
Description: There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive inactive (sham) TMS. Tics and urges will be monitored immediately before and after TMS.
Study NCT03626740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraCal
Description: Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with TheraCal
Study NCT03626740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with MTA
Study NCT02067143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 5 Consolidation
Study NCT02067143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 6 Consolidation
Study NCT02067143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 7 Consolidation
Study NCT02067143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 8 Reinduction
Study NCT02067143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance
Description: If MRD negative MRD u/k SR
Study NCT02067143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic SCT or Autologous SCT
Description: If MRD positive MRD u/k HR
Study NCT02041299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Study NCT02041299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Study NCT04254146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
Study NCT04254146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
Study NCT01313910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunolin®
Description: Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks
Study NCT02172391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium inhalation powder capsules
Study NCT01102374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Study NCT01125657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study NCT02172391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation powder capsules
Study NCT04163978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: in situ 240mL nitric oxide releasing sinus irrigation solution
Study NCT04163978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Saline based sinus irrigation 1mg Budesinide solution
Study NCT02869334 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial direct current stimulation (tDCS)
Description: Sham (inactive or placebo) tDCS
Study NCT04913480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 750mg intravenous infusion once every 2 weeks for 26 cycles
Study NCT04913480 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Stereotactic body radiation therapy of 27.5Gy to 50Gy in 5 fractions to the liver tumors delivered over 5 to 14 days.
Study NCT03815149 — intervention group
Intervention type: DEVICE
Intervention: Pipeline™ Flex Embolization Device with Shield Technology™
Description: Neurointerventional procedures to treat intracranial (cerebral) aneurysms are minimally-invasive procedures performed by Interventional Neuroradiologists. The physician accesses the arterial system through a blood vessel in the groin followed by the insertion of a catheter. Pipeline™ Flex Embolization Device(s) with Shield Technology™,a flow diversion device, is implanted under high-magnification subtraction fluoroscopy, requiring the use of ancillary devices, such as micro-catheters and guidewires to complete the procedure under general anaesthetic. Procedural heparinisation and preloading with dual antiplatelet therapy (DAPT) using acetyl-salicylic acid and P2Y12 inhibitors such as clopidogrel or prasugrel are required.
Study NCT03468777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
Study NCT02869334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Remediation
Description: Computer program designed to improve discrimination between sounds
Study NCT02869334 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control computer activities
Description: Computer program (e.g. games), which are not designed to improve discrimination between sounds
Study NCT00421889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Study NCT00421889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT00421889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT03468777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.
Study NCT03149926 — intervention group
Intervention type: OTHER
Intervention: Stimuli presentation
Description: Different stimuli associated with self-injury are presented. Participants have to rate the emotional effect elected by the stimuli.
Study NCT01966263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIA of the posterior capsule of the knee
Description: the surgeon infiltrates the posterior capsule of the knee using 100 mL ropivacaine 0.2% with 0.5 mg epinephrine.
Study NCT01966263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIA of the anterior capsule of the knee
Description: the surgeon infiltrates the anterior capsule of the knee using 50 mL ropivacaine 0.2% with 0.25 mg epinephrine.
Study NCT01966263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIA of the subcutaneous tissue of the knee
Description: the surgeon infiltrates the subcutaneous tissue of the knee using 50 mL ropivacaine 0.2% before wound closure.
Study NCT01966263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNB with catheter
Description: pre-operatively the anesthesiologist will ultrasound guided place a catheter close to the femoral nerve using sodium chloride (NaCl 0.9%) (no local anesthetic). During surgery, when the LIA of the posterior capsule is performed, 20 mL ropivacaine 0.2% will be administered through the catheter to create a femoral nerve block (FNB). Postoperatively patients will receive 20 mL ropivacaine 0.2% through the catheter 6 times daily for 24 hours
Study NCT03296436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEOX® CORD 1K®
Description: NEOX CORD 1K is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. NEOX CORD 1K is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. NEOX CORD 1K is aseptically processed in compliance with current Good Tissue Practices (cGTP). NEOX CORD 1K of various sizes is stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B (an anti-fungal agent). NEOX CORD 1K will be applied to completely cover the wound area and is maintained stationary with sutures or even negative pressure wound therapy after adequate sharp debridement.
Study NCT03290365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma + Hyaluronic acid
Description: Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee.
Study NCT03290365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: platelet rich plasma + normal saline
Description: The normal salin as the placebo intervention was injection control group.
Study NCT03058419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446 150 mg
Description: Subjects will receive JNJ-54175446 150 mg capsules orally (1\*100 mg + 1\*50 mg) under fasted conditions on Day 7, 9, 10 and 11.
Study NCT03058419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446 600 mg
Description: Subjects will receive JNJ-54175446 600 mg (6\*100 mg capsules) orally on Day 8.
Study NCT03058419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg
Description: Subjects will receive midazolam 2 mg oral emulsion \[2 (milligram per milliliter (mg/mL)\] as a drug cocktail on Day 1, 7 and 11.
Study NCT03058419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin 10 mg
Description: Subjects will receive warfarin 10 mg tablets (2\*5 mg) orally as a drug cocktail on Day 1, 7 and 11.
Study NCT03058419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine 50 mg
Description: Subjects will receive caffeine 50 mg tablet (1\*50 mg) orally as a drug cocktail on Day 1, 7 and 11.
Study NCT03058419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Description: Subjects will receive dextromethorphan 30 mg capsule (1\*30 mg) orally as a drug cocktail on Day 1, 7 and 11.
Study NCT03058419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion 150 mg
Description: Subjects will receive Bupropion 150 mg tablet (1\*150 mg) orally as a drug cocktail on Day 1, 7 and 11.
Study NCT03058419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Description: Subjects will receive omeprazole 20 mg capsule (1\*20 mg) orally as a drug cocktail on Day 1, 7 and 11.
Study NCT00776165 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human GCSF (Shantha Biotechnics Limited)
Description: Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
Study NCT00776165 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Neupogen
Description: Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
Study NCT04040153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guiding Good Choices
Description: Guiding Good Choices is a 5-session group-based prevention program for parents of early adolescents. Weekly 2.5 hour sessions will be held at participants' primary care clinics and led by two trained interventionists. Through didactic material, video segments, interactive activities, and home practice, the curriculum teaches parents to understand the progression from individual and environmental risk and protective factors to substance use and problem behavior, enhances parenting behaviors and skills, teaches effective family management skills, strengthens parent-adolescent interactions and bonding, broadens opportunities for family involvement, teaches conflict reduction and anger management skills, and teaches adolescents skills to resist peer influences to engage in risky behavior. Parents who opt not to attend groups will be offered a self-guided intervention manual containing the same core content and video access, plus supportive coaching to motivate use and address questions.
Study NCT00497952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hematopoetic stem cell infusion
Description: Enriched hematopoietic stem cell infusion
Study NCT00937820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study NCT02603302 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose Escalation Radiotherapy
Description: RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV Chemotherapy with 5-FU
Study NCT02603302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed surgery
Description: Surgery after 8 weeks with TME (total mesorectal excision)
Study NCT00569621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxaverine
Description: intravenous administration
Study NCT03468777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.
Study NCT00996658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching linagliptin tablets once daily
Study NCT00996658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin tablets once daily
Study NCT04339413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab was administered as SC injection Q4W.
Study NCT01337193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises with biofeedback
Description: Exercises will be performed with assistance of biofeedback cueing
Study NCT01337193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle exercises
Description: Exercises will b performed with verbal cueing of investigator.
Study NCT02088853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high fat diet (hfd)
Description: Sixty % of the energy content is based on fat.
Study NCT01515436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mozart alternating with Beethoven
Description: Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
Study NCT01515436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beethoven alternating with Mozart
Description: Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
Study NCT02088853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high carb diet
Description: Sixty % of the energy content is based on carbohydrates.
Study NCT00903422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eltrombopag olamine
Description: thrombopoietin receptor agonist
Study NCT00903422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets with no active pharmaceutical ingredient
Study NCT00581022 — intervention group
Intervention type: PROCEDURE
Intervention: Polysomnography
Description: Overnight Sleep Study
Study NCT00958477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 525797
Description: Subjects will be administered with 250 milligram (mg), 500 mg, 1000 mg or 1500 mg of EMD 525797 intravenously over 1 hour every 2 weeks for 6 weeks. Subjects who will be clinically benefitted at the end of week 6 were continued at the same dose-level until disease progression, intolerance to treatment, withdrawal of consent or if the subject is no longer benefitted from the treatment as per Investigator's discretion.
Study NCT04003844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin G
Description: single dose of IGIV 10% (2 g/kg) administered intravenously for at least 12 hours
Study NCT04003844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Coadministration
Study NCT04571060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant
Description: One dose of zavegepant
Study NCT04571060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of matching placebo
Study NCT02186483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin,1000mg, once daily
Study NCT02186483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin, 20 mg, once daily
Study NCT02186483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Rosuvastatin
Description: Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily
Study NCT00442416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: As prescribed, SC
Study NCT00442416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 120-360 micrograms SC monthly, starting dose
Study NCT03920241 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mindfulness-Based Stress Reduction
Description: The MBSR is an 8-week standardized program (Kabat-Zinn, 1990) consisted of 2.5-hour of face-to-face weekly sessions, and 45 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. During the program, different mindfulness practices are performed, including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga.~Training is delivered by certificated instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/).